Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Coherus Oncology, Inc. (CHRS)
USD1.43
-0.02 (-1.17%)
US NASDAQ S&P 500
Healthcare Biotechnology
Address
333 Twin Dolphin Drive 94065
Redwood City, CA, US
Redwood City, CA, US
CEO
Dennis Lanfear
Website
coherus.com
IPO
2014-11-06
CIK 1512762 ISIN US19249H1032
Description
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| General Motors Company | GM | 2023-07-07 | View |
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 1987-02-12 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.43
-0.02 (-1.17%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.98
Float Shares
126.21M
Free Float %
107.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +11.43% | +10.80% | +16.07% | -2.99% | +43.38% | +37.32% | +91.18% | -60.20% | -85.92% | -87.83% | -84.54% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (16 ratings, all time)
Buy
Price Targets & DCF
Current price
1.43
Low
1.05
-26.7%
Consensus
6.02
+320.1%
Median
6.00
+318.7%
High
11.00
+667.6%
Ratings Trend (MoM)
86% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | +1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 4 |
6.26
+336.8%
|
Quality scores
Altman Z-Score
-8.30
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
3 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-84.2% Q1'26: +62.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-680.0% Q1'26: +42.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-438.8% Q1'26: -470.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-412.9% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.8% Q1'26: +17.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.24× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 2 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
30.04M
est: 26.82M (+12.0%)
|
190.11M
est: 205.94M (-7.7%)
|
1.56M
est: 4.65M (-66.6%)
|
356.07M
est: 357.25M (-0.3%)
|
475.82M
est: 480.32M (-0.9%)
|
326.55M
est: 335.74M (-2.7%)
|
211.04M
est: 213.31M (-1.1%)
|
257.24M
est: 308.13M (-16.5%)
|
266.96M
est: 256.37M (+4.1%)
|
42.17M
est: 43.47M (-3.0%)
|
81.63M
56.55M – 128.64M
+87.8% YoY
|
111.08M
88.79M – 122.82M
+36.1% YoY
|
183.83M
182.13M – 185.52M
+65.5% YoY
|
260.53M
208.83M – 354.43M
+41.7% YoY
|
356.78M
285.98M – 485.38M
+36.9% YoY
|
| EBITDA |
-222.04M
est: -10.64M (-1,986.4%)
|
-116.81M
est: -81.71M (-43.0%)
|
-225.34M
est: -1.85M (-12,104.3%)
|
111.03M
est: -141.74M (+178.3%)
|
161.84M
est: 154.41M (+4.8%)
|
-260.69M
est: -5.91B (+95.6%)
|
-255.58M
est: -170.66M (-49.8%)
|
-193.94M
est: -204.84M (+5.3%)
|
60.94M
est: -170.43M (+135.8%)
|
-170.20M
est: -28.90M (-488.9%)
|
-54.27M
-85.52M – -37.60M
-87.8% YoY
|
-73.85M
-81.65M – -59.03M
-36.1% YoY
|
-122.21M
-123.33M – -121.08M
-65.5% YoY
|
-173.20M
-235.62M – -138.83M
-41.7% YoY
|
-237.19M
-322.67M – -190.12M
-36.9% YoY
|
| EBIT |
-223.91M
est: -10.94M (-1,946.7%)
|
-119.81M
est: -84.00M (-42.6%)
|
-228.73M
est: -1.90M (-11,951.1%)
|
107.77M
est: -145.71M (+174.0%)
|
156.87M
est: 150.86M (+4.0%)
|
-264.14M
est: -5.94B (+95.6%)
|
-259.28M
est: -169.88M (-52.6%)
|
-197.73M
est: -207.62M (+4.8%)
|
55.67M
est: -172.74M (+132.2%)
|
-174.12M
est: -29.29M (-494.4%)
|
-55.01M
-86.68M – -38.11M
-87.8% YoY
|
-74.85M
-82.76M – -59.83M
-36.1% YoY
|
-123.86M
-125.00M – -122.72M
-65.5% YoY
|
-175.55M
-238.82M – -140.71M
-41.7% YoY
|
-240.40M
-327.05M – -192.69M
-36.9% YoY
|
| Net Income |
-223.26M
est: -734.35M (+69.6%)
|
-127.34M
est: -370.80M (+65.7%)
|
-238.17M
est: -527.25M (+54.8%)
|
89.83M
est: 160.65M (-44.1%)
|
132.24M
est: 124.92M (+5.9%)
|
-287.10M
est: -6.15B (+95.3%)
|
-291.75M
est: -264.12M (-10.5%)
|
-237.89M
est: -29.34M (-710.8%)
|
28.51M
est: 42.51M (-32.9%)
|
-170.29M
est: -183.12M (+7.0%)
|
-146.82M
-170.25M – -86.02M
+19.8% YoY
|
-145.18M
-162.04M – -81.87M
+1.1% YoY
|
-73.42M
-104.72M – -42.13M
+49.4% YoY
|
-35.67M
-52.38M – -26.47M
+51.4% YoY
|
36.38M
26.99M – 53.42M
+202.0% YoY
|
| SGA |
36.05M
est: 16.30M (+121.2%)
|
51.60M
est: 125.11M (-58.8%)
|
71.30M
est: 2.83M (+2,422.1%)
|
137.04M
est: 217.03M (-36.9%)
|
139.08M
est: 150.68M (-7.7%)
|
169.71M
est: 203.96M (-16.8%)
|
198.48M
est: 174.10M (+14.0%)
|
185.62M
est: 316.20M (-41.3%)
|
150.44M
est: 263.07M (-42.8%)
|
100.60M
est: 44.61M (+125.5%)
|
83.77M
58.03M – 132.01M
+87.8% YoY
|
113.99M
91.12M – 126.03M
+36.1% YoY
|
188.64M
186.90M – 190.37M
+65.5% YoY
|
267.35M
214.29M – 363.70M
+41.7% YoY
|
366.12M
293.46M – 498.08M
+36.9% YoY
|
| EPS |
-6.01
est: -6.40 (+6.0%)
|
-3.04
est: -3.23 (+5.9%)
|
-4.48
est: -4.59 (+2.4%)
|
1.29
est: 1.40 (-7.8%)
|
1.85
est: 1.72 (+7.6%)
|
-3.81
est: -3.62 (-5.3%)
|
-3.76
est: -3.62 (-3.9%)
|
-2.53
est: -0.27 (-842.7%)
|
0.25
est: 0.35 (-29.2%)
|
-1.45
est: -1.54 (+5.6%)
|
-0.96
-1.41 – -0.71
+37.3% YoY
|
-0.92
-1.35 – -0.68
+4.8% YoY
|
-0.66
-0.87 – -0.35
+28.3% YoY
|
-0.30
-0.44 – -0.22
+54.9% YoY
|
0.30
0.22 – 0.44
+202.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 4/5 | 3/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-174.65M
OE per share TTM
-1.42
Owner's Yield
-65.67%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
64
Total invested
24.87M
Insider transactions (90d)
0
Beneficial owners (>5%)
22
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 11.65M | 10.90% | 11.07M | — | 11.65M | — | HC | Delaware | 2023-10-06 | ↗ |
| 2 | David Rosen | 10.40M | 9.03% | — | 10.40M | — | — | IN | State of Delaware | 2024-11-13 | ↗ |
| 3 | Rubric Capital Management LP | 10.40M | 9.03% | — | 10.40M | — | — | IA, PN | State of Delaware | 2024-11-13 | ↗ |
| 4 | Fullerton Management Pte Ltd | 7.38M | 10.53% | — | 7.38M | — | 7.38M | HC | Republic of Singapore | 2020-02-07 | ↗ |
| 5 | Temasek Holdings (Private) Limited | 7.38M | 10.53% | — | 7.38M | — | 7.38M | HC | Republic of Singapore | 2020-02-07 | ↗ |
| 6 | Temasek Life Sciences Private Limited | 7.38M | 10.53% | — | 7.38M | — | 7.38M | HC | Republic of Singapore | 2020-02-07 | ↗ |
| 7 | V-Sciences Investments Pte Ltd | 7.38M | 10.53% | — | 7.38M | — | 7.38M | CO | Republic of Singapore | 2020-02-07 | ↗ |
| 8 | JPMORGAN CHASE & CO.13-2624428 | 6.36M | 8.20% | 5.29M | — | 6.35M | — | HC | Delaware | 2022-01-07 | ↗ |
| 9 | 13-4064930 | 5.71M | 7.40% | 5.33M | — | 5.67M | — | IA | Delaware | 2022-02-14 | ↗ |
| 10 | Advisors LLC | 5.41M | 7.00% | — | 5.41M | — | — | IA | Delaware | 2022-02-15 | ↗ |
| 11 | Edelman | 5.41M | 7.00% | — | 5.41M | — | — | IN | Delaware | 2022-02-15 | ↗ |
| 12 | Sciences Master Fund, Ltd. | 5.41M | 7.00% | — | 5.41M | — | — | CO | Delaware | 2022-02-15 | ↗ |
| 13 | The Vanguard Group - 23-1945930 | 4.55M | 5.92% | — | 122.8K | 4.37M | 173.9K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 14 | STATE STREET CORPORATION | 3.82M | 4.98% | — | 3.70M | — | 3.82M | HC | BOSTON, MASSACHUSETTS | 2022-02-09 | ↗ |
| 15 | JPMORGAN CHASE & CO13-2624428 | 3.74M | 5.40% | 3.11M | — | 3.73M | — | HC | Delaware | 2019-01-09 | ↗ |
| 16 | Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but | 3.59M | 5.00% | — | 3.59M | — | — | IA | Delaware | 2020-10-07 | ↗ |
| 17 | Wellington Group Holdings LLP | 2.37M | 3.39% | — | 2.26M | — | — | HC | Massachusetts | 2019-11-08 | ↗ |
| 18 | Wellington Investment Advisors Holdings LLP | 2.37M | 3.39% | — | 2.26M | — | — | HC | Massachusetts | 2019-11-08 | ↗ |
| 19 | Wellington Management Group LLP | 2.37M | 3.39% | — | 2.26M | — | — | HC | Massachusetts | 2019-11-08 | ↗ |
| 20 | 2 | 559.2K | 0.90% | — | 559.2K | — | 559.2K | IA | Delaware | 2018-02-14 | ↗ |
| 21 | 2. | 10.00 | 0.10% | — | 50.2K | — | — | BD, OO | Delaware | 2023-05-19 | ↗ |
| 22 | 0% | — | 0.00% | — | — | — | — | CO | Japan | 2019-02-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
64
-64 vs prev Q
New positions
15
Closed positions
77
Increased
29
Reduced
17
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 900.0K +900.0K (+100.0%) | 1.28B +1.3B (+100.0%) | 0.77% +0.774 pp | 0.00% +0.002 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 10.56M +102.7K (+1.0%) | 15.00M -2.2M (-12.6%) | 9.09% +0.077 pp | 0.00% +0.000 pp | USD1.04 +36.5% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 10.03M -292.2K (-2.8%) | 14.24M -2.7M (-15.9%) | 8.63% -0.263 pp | 0.00% +0.000 pp | USD9.86 -85.6% | 45 qtrs — |
| 4 | KOHLBERG KRAVIS ROBERTS & CO. L.P. | 3.04M +— (+0.0%) | 4.25M -684.8K (-13.9%) | 2.61% -0.003 pp | 0.07% -0.015 pp | USD16.89 -91.6% | 39 qtrs — |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.75M +4.0K (+0.1%) | 3.90M -597.5K (-13.3%) | 2.36% +0.000 pp | 0.00% +0.000 pp | USD9.07 -84.3% | 45 qtrs — |
| 6 | TANG CAPITAL MANAGEMENT LLC | 2.72M -2.4M (-46.6%) | 3.87M -4.5M (-53.7%) | 2.34% -2.047 pp | 0.19% -0.131 pp | USD1.18 +20.3% | 7 qtrs — |
| 7 | STATE STREET CORP | 2.22M +20.0 (+0.0%) | 3.16M -489.1K (-13.4%) | 1.91% -0.003 pp | 0.00% +0.000 pp | USD5.86 -75.8% | 45 qtrs — |
| 8 | CM MANAGEMENT, LLC | 2.10M +— (+0.0%) | 2.98M -462.0K (-13.4%) | 1.81% -0.002 pp | 2.51% -0.358 pp | USD2.94 -51.7% | 21 qtrs — |
| 9 | C WORLDWIDE GROUP HOLDING A/S | 1.93M +— (+0.0%) | 2.74M -425.0K (-13.4%) | 1.66% -0.002 pp | 0.05% -0.001 pp | USD11.92 -88.1% | 43 qtrs — |
| 10 | PANAGORA ASSET MANAGEMENT INC | 1.62M +244.3K (+17.8%) | 2.30M +44.2K (+2.0%) | 1.39% +0.209 pp | 0.01% -0.001 pp | USD1.16 +22.4% | 3 qtrs — |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 935.2K -57.9K (-5.8%) | 1.33M -300.6K (-18.5%) | 0.80% -0.051 pp | 0.00% 0.000 pp | USD8.78 -83.8% | 45 qtrs — |
| 12 | AQR CAPITAL MANAGEMENT LLC | 885.7K -17.3K (-1.9%) | 1.26M -223.3K (-15.1%) | 0.76% -0.016 pp | 0.00% 0.000 pp | USD1.29 +10.1% | 29 qtrs — |
| 13 | HUDSON BAY CAPITAL MANAGEMENT LP | 835.0K +25.0K (+3.1%) | 1.19M -142.7K (-10.7%) | 0.72% +0.021 pp | 0.00% -0.001 pp | USD3.91 -63.7% | 15 qtrs — |
| 14 | NORTHERN TRUST CORP | 793.3K -57.1K (-6.7%) | 1.13M -268.2K (-19.2%) | 0.68% -0.050 pp | 0.00% +0.000 pp | USD13.02 -89.1% | 45 qtrs — |
| 15 | MILLENNIUM MANAGEMENT LLC | 660.5K +660.5K (+100.0%) | 937.8K +937.8K (+100.0%) | 0.57% +0.568 pp | 0.00% +0.000 pp | USD1.42 +0.0% | 20 qtrs — |
| 16 | UBS GROUP AG | 610.8K -185.1K (-23.3%) | 867.3K -438.0K (-33.6%) | 0.53% -0.160 pp | 0.00% 0.000 pp | USD1.47 -3.4% | 45 qtrs — |
| 17 | JANE STREET GROUP, LLC | 603.5K +393.5K (+187.4%) | 857.0K +512.6K (+148.9%) | 0.52% +0.338 pp | 0.00% +0.000 pp | USD1.40 +1.4% | 22 qtrs — |
| 18 | TWO SIGMA INVESTMENTS, LP | 503.9K +468.2K (+1,310.9%) | 715.5K +656.9K (+1,121.7%) | 0.43% +0.403 pp | 0.00% +0.001 pp | USD1.44 -1.4% | 2 qtrs — |
| 19 | GSA CAPITAL PARTNERS LLP | 477.5K +477.5K (+100.0%) | 678.0K +678.0K (+100.0%) | 0.41% +0.411 pp | 0.06% +0.058 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 20 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 441.0K +186.0K (+72.9%) | 626.2K +208.0K (+49.7%) | 0.38% +0.160 pp | 0.01% +0.004 pp | USD1.50 -5.3% | 7 qtrs — |
| 21 | JEFFERIES FINANCIAL GROUP INC. | 395.2K +69.6K (+21.4%) | 561.2K +27.1K (+5.1%) | 0.34% +0.060 pp | 0.00% +0.000 pp | USD2.05 -30.7% | 13 qtrs — |
| 22 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 382.2K -21.7K (-5.4%) | 542.8K -119.6K (-18.1%) | 0.33% -0.019 pp | 0.00% +0.000 pp | USD1.55 -8.4% | 29 qtrs — |
| 23 | INVESCO LTD. | 380.0K +119.0K (+45.6%) | 539.6K +111.6K (+26.1%) | 0.33% +0.102 pp | 0.00% +0.000 pp | USD2.66 -46.6% | 28 qtrs — |
| 24 | BARCLAYS PLC | 345.6K -2.1M (-86.0%) | 490.7K -2.1M (-80.9%) | 0.30% -1.827 pp | 0.00% -0.001 pp | USD1.77 -19.8% | 45 qtrs — |
| 25 | STRS OHIO | 324.0K +— (+0.0%) | 460.1K -71.3K (-13.4%) | 0.28% 0.000 pp | 0.00% 0.000 pp | USD1.20 +18.3% | 7 qtrs — |
| 26 | TWO SIGMA ADVISERS, LP | 307.6K +295.1K (+2,360.8%) | 436.8K +416.3K (+2,030.7%) | 0.26% +0.254 pp | 0.00% +0.001 pp | USD1.43 -0.7% | 2 qtrs — |
| 27 | GOLDMAN SACHS GROUP INC | 307.1K -75.6K (-19.8%) | 436.1K -191.6K (-30.5%) | 0.26% -0.066 pp | 0.00% +0.000 pp | USD3.87 -63.3% | 44 qtrs — |
| 28 | BANK OF NEW YORK MELLON CORP | 290.9K -85.8K (-22.8%) | 413.0K -204.7K (-33.1%) | 0.25% -0.074 pp | 0.00% +0.000 pp | USD11.45 -87.6% | 45 qtrs — |
| 29 | MORGAN STANLEY | 248.4K +18.0K (+7.8%) | 352.7K -25.1K (-6.6%) | 0.21% +0.015 pp | 0.00% +0.000 pp | USD2.51 -43.4% | 45 qtrs — |
| 30 | TYCHE WEALTH PARTNERS LLC | 220.9K +25.0K (+12.8%) | 313.6K -7.6K (-2.4%) | 0.19% +0.021 pp | 0.05% -0.007 pp | USD2.78 -48.9% | 9 qtrs — |
| 31 | ALLIANCEBERNSTEIN L.P. | 213.6K +— (+0.0%) | 303.3K -47.0K (-13.4%) | 0.18% 0.000 pp | 0.00% +0.000 pp | USD11.69 -87.9% | 44 qtrs — |
| 32 | NUVEEN, LLC | 210.4K +76.6K (+57.3%) | 298.7K +79.4K (+36.2%) | 0.18% +0.066 pp | 0.00% +0.000 pp | USD1.18 +20.3% | 4 qtrs — |
| 33 | CITIGROUP INC | 192.9K -51.2K (-21.0%) | 273.9K -126.5K (-31.6%) | 0.17% -0.044 pp | 0.00% 0.000 pp | USD3.85 -63.1% | 45 qtrs — |
| 34 | XTX TOPCO LTD | 166.8K +69.6K (+71.6%) | 236.9K +77.5K (+48.6%) | 0.14% +0.060 pp | 0.01% -0.002 pp | USD1.30 +9.2% | 10 qtrs — |
| 35 | LOS ANGELES CAPITAL MANAGEMENT LLC | 131.4K +43.4K (+49.4%) | 223.3K +79.1K (+54.8%) | 0.11% +0.037 pp | 0.00% +0.000 pp | USD1.46 -2.7% | 10 qtrs — |
| 36 | RENAISSANCE TECHNOLOGIES LLC | 137.9K +113.8K (+472.2%) | 195.8K +156.3K (+395.4%) | 0.12% +0.098 pp | 0.00% +0.000 pp | USD1.31 +8.4% | 8 qtrs — |
| 37 | CITADEL ADVISORS LLC | 132.1K +53.8K (+68.7%) | 187.6K +59.2K (+46.1%) | 0.11% +0.046 pp | 0.00% +0.000 pp | USD1.58 -10.1% | 13 qtrs — |
| 38 | RHUMBLINE ADVISERS | 131.5K -23.8K (-15.3%) | 186.7K -68.0K (-26.7%) | 0.11% -0.021 pp | 0.00% 0.000 pp | USD11.13 -87.2% | 43 qtrs — |
| 39 | WELLS FARGO & COMPANY/MN | 118.0K +41.9K (+55.1%) | 167.5K +42.8K (+34.3%) | 0.10% +0.036 pp | 0.00% +0.000 pp | USD2.21 -35.7% | 44 qtrs — |
| 40 | BANK OF AMERICA CORP /DE/ | 111.7K +35.9K (+47.4%) | 158.6K +34.3K (+27.6%) | 0.10% +0.031 pp | 0.00% +0.000 pp | USD1.97 -27.9% | 44 qtrs — |
| 41 | LPL FINANCIAL LLC | 98.5K -120.6K (-55.0%) | 139.9K -219.5K (-61.1%) | 0.08% -0.104 pp | 0.00% 0.000 pp | USD1.41 +0.7% | 9 qtrs — |
| 42 | HSBC HOLDINGS PLC | 94.4K +2.4K (+2.6%) | 135.4K -14.1K (-9.4%) | 0.08% +0.002 pp | 0.00% +0.000 pp | USD5.24 -72.9% | 16 qtrs — |
| 43 | SQUAREPOINT OPS LLC | 92.8K +92.8K (+100.0%) | 131.7K +131.7K (+100.0%) | 0.08% +0.080 pp | 0.00% +0.000 pp | USD1.42 +0.0% | 3 qtrs — |
| 44 | CI PRIVATE WEALTH, LLC | 90.0K +— (+0.0%) | 127.8K -19.8K (-13.4%) | 0.08% 0.000 pp | 0.00% 0.000 pp | USD1.40 +1.4% | 7 qtrs — |
| 45 | MARSHALL WACE, LLP | 85.5K +85.5K (+100.0%) | 121.4K +121.4K (+100.0%) | 0.07% +0.074 pp | 0.00% +0.000 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 46 | IEQ CAPITAL, LLC | 79.1K +15.8K (+24.9%) | 112.4K +8.4K (+8.1%) | 0.07% +0.014 pp | 0.00% +0.000 pp | USD1.22 +16.4% | 5 qtrs — |
| 47 | SEI INVESTMENTS CO | 76.6K +76.6K (+100.0%) | 108.8K +108.8K (+100.0%) | 0.07% +0.066 pp | 0.00% +0.000 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 48 | DEUTSCHE BANK AG\ | 71.8K -46.2K (-39.2%) | 101.9K -91.6K (-47.3%) | 0.06% -0.040 pp | 0.00% +0.000 pp | USD1.73 -17.9% | 45 qtrs — |
| 49 | STEEL PEAK WEALTH MANAGEMENT LLC | 69.0K +— (+0.0%) | 98.0K -15.2K (-13.4%) | 0.06% 0.000 pp | 0.00% -0.001 pp | USD5.01 -71.7% | 13 qtrs — |
| 50 | PRICE T ROWE ASSOCIATES INC /MD/ | 59.6K +— (+0.0%) | 85.0K -13.0K (-13.3%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD6.01 -76.4% | 38 qtrs — |
| 51 | JPMORGAN CHASE & CO | 51.2K -56.4K (-52.5%) | 72.6K -103.8K (-58.8%) | 0.04% -0.049 pp | 0.00% +0.000 pp | USD3.74 -62.0% | 45 qtrs — |
| 52 | ACADIAN ASSET MANAGEMENT LLC | 51.6K +— (+0.0%) | 72.0K -12.0K (-14.3%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD0.81 +75.3% | 6 qtrs — |
| 53 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 49.3K -5.0 (0.0%) | 70.0K -10.8K (-13.4%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD1.51 -6.0% | 7 qtrs — |
| 54 | INTECH INVESTMENT MANAGEMENT LLC | 48.1K +— (+0.0%) | 68.2K -10.6K (-13.4%) | 0.04% 0.000 pp | 0.00% 0.000 pp | USD0.98 +44.9% | 5 qtrs — |
| 55 | SIMPLEX TRADING, LLC | 48.0K -10.8K (-18.3%) | 68.2K -27.8K (-28.9%) | 0.04% -0.009 pp | 0.00% +0.000 pp | USD1.61 -11.8% | 42 qtrs — |
| 56 | INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 44.8K -906.0 (-2.0%) | 63.6K +28.9K (+83.1%) | 0.04% -0.001 pp | 0.00% +0.002 pp | USD0.73 +94.5% | 10 qtrs — |
| 57 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 43.7K -6.3K (-12.7%) | 62.0K -20.0K (-24.4%) | 0.04% -0.006 pp | 0.00% 0.000 pp | USD2.19 -35.2% | 19 qtrs — |
| 58 | GROUP ONE TRADING, L.P. | 41.2K -14.0K (-25.3%) | 58.5K -32.0K (-35.3%) | 0.04% -0.012 pp | 0.00% 0.000 pp | USD0.81 +75.3% | 29 qtrs — |
| 59 | CWM, LLC | 40.3K +4.9K (+13.8%) | 57.0K -1.0K (-1.7%) | 0.03% +0.004 pp | 0.00% +0.000 pp | USD1.05 +35.2% | 7 qtrs — |
| 60 | O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 37.2K -25.9K (-41.1%) | 52.8K -50.7K (-49.0%) | 0.03% -0.022 pp | 0.00% 0.000 pp | USD1.64 -13.4% | 2 qtrs — |
| 61 | CARR FINANCIAL GROUP CORP | 35.2K +— (+0.0%) | 50.0K -7.7K (-13.4%) | 0.03% +0.000 pp | 0.01% -0.003 pp | USD3.33 -57.4% | 9 qtrs — |
| 62 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 34.8K +373.0 (+1.1%) | 49.5K -7.1K (-12.5%) | 0.03% +0.000 pp | 0.00% 0.000 pp | USD1.36 +4.4% | 5 qtrs — |
| 63 | SG AMERICAS SECURITIES, LLC | 34.4K +22.5K (+188.3%) | 49.0K +29.0K (+145.0%) | 0.03% +0.019 pp | 0.00% +0.000 pp | USD1.50 -5.3% | 9 qtrs — |
| 64 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 34.1K +629.0 (+1.9%) | 48.4K -6.5K (-11.8%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD1.64 -13.4% | 44 qtrs — |
| 65 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 33.7K +5.3K (+18.7%) | 45.8K -2.7K (-5.6%) | 0.03% +0.005 pp | 0.00% +0.000 pp | USD1.21 +17.4% | 6 qtrs — |
| 66 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 28.2K +— (+0.0%) | 40.1K -6.2K (-13.4%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.38 +2.9% | 5 qtrs — |
| 67 | DIVERSIFIED TRUST CO | 28.2K +— (+0.0%) | 40.0K -6.2K (-13.4%) | 0.02% +0.000 pp | 0.00% 0.000 pp | USD0.73 +94.5% | 3 qtrs — |
| 68 | BNP PARIBAS ARBITRAGE, SNC | 25.2K -1.4K (-5.3%) | 35.8K -7.9K (-18.0%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD1.57 -9.6% | 44 qtrs — |
| 69 | PROSHARE ADVISORS LLC | 24.7K +6.6K (+36.3%) | 35.1K +5.4K (+18.0%) | 0.02% +0.006 pp | 0.00% +0.000 pp | USD6.35 -77.6% | 41 qtrs — |
| 70 | NEW YORK STATE COMMON RETIREMENT FUND | 20.6K +— (+0.0%) | 29.2K -4.5K (-13.4%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD16.41 -91.3% | 43 qtrs — |
| 71 | KESTRA PRIVATE WEALTH SERVICES, LLC | 20.0K +20.0K (+100.0%) | 28.4K +28.4K (+100.0%) | 0.02% +0.017 pp | 0.00% +0.000 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 72 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 19.7K +19.7K (+100.0%) | 28.0K +28.0K (+100.0%) | 0.02% +0.017 pp | 0.00% +0.002 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 73 | BOOTHBAY FUND MANAGEMENT, LLC | 19.3K +— (+0.0%) | 27.4K -4.2K (-13.4%) | 0.02% +0.000 pp | 0.00% 0.000 pp | USD3.12 -54.5% | 11 qtrs — |
| 74 | BRONTE CAPITAL MANAGEMENT PTY LTD. | 19.3K +19.3K (+100.0%) | 27.4K +27.4K (+100.0%) | 0.02% +0.017 pp | 0.00% +0.003 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 75 | BLAIR WILLIAM & CO/IL | 19.0K +19.0K (+100.0%) | 27.0K +27.0K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 76 | VOYA INVESTMENT MANAGEMENT LLC | 17.0K +— (+0.0%) | 24.1K -3.7K (-13.4%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.64 -13.4% | 43 qtrs — |
| 77 | CERITY PARTNERS LLC | 16.6K +2.8K (+20.7%) | 23.6K +1.0K (+4.5%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD1.15 +23.5% | 6 qtrs — |
| 78 | STRATOS WEALTH PARTNERS, LTD. | 16.1K -18.0 (-0.1%) | 22.9K -3.6K (-13.5%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD1.38 +2.9% | 5 qtrs — |
| 79 | PROVIDENCE WEALTH ADVISORS, LLC | 15.0K +— (+0.0%) | 21.7K -4.4K (-17.0%) | 0.01% +0.000 pp | 0.01% -0.003 pp | USD1.05 +35.2% | 6 qtrs — |
| 80 | — | 14.7K +14.7K (+100.0%) | 20.9K +20.9K (+100.0%) | 0.01% +0.013 pp | 0.01% +0.007 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 81 | TWO SIGMA SECURITIES, LLC | 14.6K -119.0 (-0.8%) | 20.7K -3.4K (-14.1%) | 0.01% 0.000 pp | 0.00% -0.001 pp | USD1.64 -13.4% | 2 qtrs — |
| 82 | WEALTH GROUP, LTD. | 14.2K +14.2K (+100.0%) | 20.0K +20.0K (+100.0%) | 0.01% +0.012 pp | 0.02% +0.020 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 83 | CAPTRUST FINANCIAL ADVISORS | 13.1K +2.4K (+21.9%) | 18.6K +972.0 (+5.5%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD1.69 -16.0% | 11 qtrs — |
| 84 | NEUBERGER BERMAN GROUP LLC | 13.0K -4.2K (-24.3%) | 18.4K -9.7K (-34.5%) | 0.01% -0.004 pp | 0.00% +0.000 pp | USD0.79 +79.7% | 4 qtrs — |
| 85 | VICTORY CAPITAL MANAGEMENT INC | 11.8K +11.8K (+100.0%) | 16.8K +16.8K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 86 | ENDOWMENT WEALTH MANAGEMENT, INC. | 11.5K +11.5K (+100.0%) | 16.4K +16.4K (+100.0%) | 0.01% +0.010 pp | 0.01% +0.008 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 87 | STONEX GROUP INC. | 11.0K +11.0K (+100.0%) | 15.6K +15.6K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.001 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 88 | MARINER, LLC | 10.9K +10.9K (+100.0%) | 15.4K +15.4K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD1.42 +0.0% | 1 qtrs NEW |
| 89 | ADAR1 CAPITAL MANAGEMENT, LLC | 10.4K +— (+0.0%) | 14.7K -2.3K (-13.4%) | 0.01% +0.000 pp | 0.00% -0.001 pp | USD0.73 +94.5% | 3 qtrs — |
| 90 | HRT FINANCIAL LP | 10.5K +10.5K (+100.0%) | 14.0K +14.0K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD1.42 +0.0% | 3 qtrs — |
| 91 | AMERITAS INVESTMENT PARTNERS, INC. | 9.8K +— (+0.0%) | 13.9K -2.2K (-13.4%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD12.25 -88.4% | 36 qtrs — |
| 92 | LEGAL & GENERAL GROUP PLC | 9.3K +— (+0.0%) | 13.2K -2.0K (-13.4%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD12.04 -88.2% | 43 qtrs — |
| 93 | RUSSELL INVESTMENTS GROUP, LTD. | 8.8K +— (+0.0%) | 12.5K -1.9K (-13.4%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.64 -13.4% | 2 qtrs — |
| 94 | TOWER RESEARCH CAPITAL LLC (TRC) | 8.1K +1.0K (+14.8%) | 11.5K -71.0 (-0.6%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD1.08 +31.5% | 26 qtrs — |
| 95 | FMR LLC | 7.8K -479.0 (-5.8%) | 11.1K -2.5K (-18.4%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD3.28 -56.7% | 45 qtrs — |
| 96 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 7.4K +— (+0.0%) | 10.4K -1.6K (-13.4%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD2.00 -29.0% | 8 qtrs — |
| 97 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 6.5K -1.5K (-18.2%) | 9.3K -3.8K (-29.2%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD15.60 -90.9% | 45 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 51 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.48% | 106.2K | 0.20% |
| 2 | iShares Micro-Cap ETF IWC | 0.05% | 674.6K | 0.60% |
| 3 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.02% | 75.6K | 0.40% |
| 4 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.02% | 12.2K | 0.19% |
| 5 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.02% | 12.0K | 0.35% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.02% | 178.6K | 0.35% |
| 7 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.01% | 323.7K | 0.34% |
| 8 | ProShares Ultra Nasdaq Biotechnology BIB | 0.01% | 8.0K | 1.19% |
| 9 | iShares Russell 2000 Value ETF IWN | 0.01% | 1.13M | 0.24% |
| 10 | Vanguard Russell 2000 Value ETF VTWV | 0.01% | 91.0K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
13.6K
Cash buys
—
Cash sales
—
Net activity
-13,554
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-23 | Lanfear Dennis M | Director / Officer | A-Award | A | Common Stock | 375,000 | 0.00 | — | 1,048,235 | D | ↗ |
| 2026-01-22 | McMichael Bryan J | Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 1.59 | 357.8K | 225,000 | D | ↗ |
| 2026-01-20 | McMichael Bryan J | Officer | F-InKind | D | Common Stock | 1,715 | 1.55 | 2.7K | 21,236 | D | ↗ |
| 2026-01-20 | Lanfear Dennis M | Director / Officer | F-InKind | D | Common Stock | 11,839 | 1.55 | 18.4K | 673,235 | D | ↗ |
| 2025-06-12 | Wahlstrom Mats | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 0.79 | 88.5K | 112,000 | D | ↗ |
| 2025-06-12 | Satvat Ali J. | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 0.79 | 88.5K | 112,000 | D | ↗ |
| 2025-06-12 | Ryan Michael Lee | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 0.79 | 88.5K | 112,000 | D | ↗ |
| 2025-06-12 | O'Donnell-Tormey Jill | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 0.79 | 88.5K | 112,000 | D | ↗ |
| 2025-06-12 | Newton Charles W. | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 0.79 | 88.5K | 112,000 | D | ↗ |
| 2025-06-12 | Newcomer Lee Nisley | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 0.79 | 88.5K | 112,000 | D | ↗ |
| 2025-06-12 | Karachun Rita A | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 0.79 | 88.5K | 112,000 | D | ↗ |
| 2025-06-12 | Erbez Georgia | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 0.79 | 88.5K | 112,000 | D | ↗ |
| 2025-05-23 | Wahlstrom Mats | Director | S-Sale | D | Common Stock | 99,988 | 0.74 | 73.9K | 0 | I | ↗ |
| 2025-05-07 | McMichael Bryan J | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.95 | 189.2K | 200,000 | D | ↗ |
| 2025-05-07 | Lanfear Dennis M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 375,000 | 0.95 | 354.8K | 375,000 | D | ↗ |
| 2025-01-20 | Reider Paul | Officer | F-InKind | D | Common Stock | 4,858 | 1.39 | 6.8K | 82,069 | D | ↗ |
| 2025-01-20 | McMichael Bryan J | Officer | F-InKind | D | Common Stock | 1,711 | 1.39 | 2.4K | 22,951 | D | ↗ |
| 2025-01-20 | Lanfear Dennis M | Director / Officer | F-InKind | D | Common Stock | 11,810 | 1.39 | 16.4K | 685,074 | D | ↗ |
| 2025-01-10 | Lanfear Dennis M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 575,000 | 1.47 | 845.3K | 575,000 | D | ↗ |
| 2025-01-07 | McMichael Bryan J | Officer | F-InKind | D | Common Stock | 1,711 | 1.57 | 2.7K | 24,662 | D | ↗ |
| 2025-01-04 | Reider Paul | Officer | F-InKind | D | Common Stock | 2,277 | 1.66 | 3.8K | 86,927 | D | ↗ |
| 2025-01-04 | Lanfear Dennis M | Director / Officer | F-InKind | D | Common Stock | 11,810 | 1.66 | 19.6K | 696,884 | D | ↗ |
| 2025-01-03 | Reider Paul | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 1.66 | 265.6K | 160,000 | D | ↗ |
| 2025-01-03 | McMichael Bryan J | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 1.66 | 265.6K | 160,000 | D | ↗ |
| 2024-12-13 | Reider Paul | Officer | F-InKind | D | Common Stock | 2,073 | 1.61 | 3.3K | 89,204 | D | ↗ |
| 2024-08-07 | McMichael Bryan J | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 1.24 | 93.0K | 75,000 | — | ↗ |
| 2024-07-22 | Reider Paul | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.41 | 96.4K | 40,000 | — | ↗ |
| 2024-07-22 | Lanfear Dennis M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 196,500 | 2.41 | 473.6K | 196,500 | — | ↗ |
| 2024-06-04 | Karachun Rita A | Director | A-Award | A | Stock Option (Right to Buy) | 168,000 | 1.78 | 299.0K | 168,000 | — | ↗ |
| 2024-06-04 | Erbez Georgia | Director | A-Award | A | Stock Option (Right to Buy) | 114,000 | 1.78 | 202.9K | 114,000 | — | ↗ |
| 2024-06-03 | Wahlstrom Mats | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 1.76 | 197.1K | 112,000 | — | ↗ |
| 2024-06-03 | TZOUMAKAS KIMBERLY JO | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 1.76 | 197.1K | 112,000 | — | ↗ |
| 2024-06-03 | STOLPER MARK | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 1.76 | 197.1K | 112,000 | — | ↗ |
| 2024-06-03 | Ryan Michael Lee | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 1.76 | 197.1K | 112,000 | — | ↗ |
| 2024-06-03 | O'Donnell-Tormey Jill | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 1.76 | 197.1K | 112,000 | — | ↗ |
| 2024-06-03 | Newton Charles W. | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 1.76 | 197.1K | 112,000 | — | ↗ |
| 2024-06-03 | Newcomer Lee Nisley | Director | A-Award | A | Stock Option (Right to Buy) | 112,000 | 1.76 | 197.1K | 112,000 | — | ↗ |
| 2024-05-31 | Karachun Rita A | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-20 | Erbez Georgia | Director | A-Award | A | Stock Option (Right to Buy) | 54,000 | 2.59 | 139.9K | 54,000 | — | ↗ |
| 2024-02-09 | Wahlstrom Mats | Director | G-Gift | D | Common Stock | 99,988 | 0.00 | — | 0 | — | ↗ |
| 2024-02-01 | Wahlstrom Mats | Director | M-Exempt | A | Common Stock | 14,997 | 1.67 | 25.0K | 54,997 | — | ↗ |
| 2024-01-20 | Reider Paul | Officer | F-InKind | D | Common Stock | 4,854 | 2.44 | 11.8K | 81,277 | — | ↗ |
| 2024-01-20 | McMichael Bryan J | Officer | F-InKind | D | Common Stock | 1,707 | 2.44 | 4.2K | 22,972 | — | ↗ |
| 2024-01-20 | Lanfear Dennis M | Director / Officer | F-InKind | D | Common Stock | 11,218 | 2.44 | 27.4K | 708,694 | — | ↗ |
| 2024-01-07 | McMichael Bryan J | Officer | F-InKind | D | Common Stock | 1,707 | 2.87 | 4.9K | 24,679 | — | ↗ |
| 2024-01-05 | Lanfear Dennis M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 575,000 | 3.14 | 1.81M | 575,000 | — | ↗ |
| 2024-01-04 | Reider Paul | Officer | F-InKind | D | Common Stock | 2,275 | 2.92 | 6.6K | 86,131 | — | ↗ |
| 2024-01-04 | Lanfear Dennis M | Director / Officer | F-InKind | D | Common Stock | 11,781 | 2.92 | 34.4K | 719,912 | — | ↗ |
| 2024-01-02 | Reider Paul | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 3.14 | 502.4K | 160,000 | — | ↗ |
| 2024-01-02 | McMichael Bryan J | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 3.14 | 392.5K | 125,000 | — | ↗ |
| 2023-12-31 | Stilwell McDavid | Officer | F-InKind | D | Common Stock | 18,440 | 3.33 | 61.4K | 75,305 | — | ↗ |
| 2023-12-13 | Reider Paul | Officer | F-InKind | D | Common Stock | 2,049 | 2.37 | 4.9K | 88,406 | — | ↗ |
| 2023-11-22 | Lanfear Dennis M | Director / Officer | S-Sale | D | Common Stock | 223,100 | 2.02 | 449.8K | 731,693 | — | ↗ |
| 2023-07-18 | Ryan Michael Lee | Director | A-Award | A | Stock Option (Right to Buy) | 54,000 | 4.39 | 237.1K | 54,000 | — | ↗ |
| 2023-06-13 | Stilwell McDavid | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 5.44 | 380.8K | 70,000 | — | ↗ |
| 2023-06-13 | Reider Paul | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 5.44 | 380.8K | 70,000 | — | ↗ |
| 2023-06-13 | McMichael Bryan J | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 5.44 | 163.2K | 30,000 | — | ↗ |
| 2023-06-13 | Lanfear Dennis M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 5.44 | 1.22M | 225,000 | — | ↗ |
| 2023-06-07 | Wahlstrom Mats | Director | A-Award | A | Stock Option (Right to Buy) | 38,250 | 5.38 | 205.8K | 38,250 | — | ↗ |
| 2023-06-07 | TZOUMAKAS KIMBERLY JO | Director | A-Award | A | Stock Option (Right to Buy) | 38,250 | 5.38 | 205.8K | 38,250 | — | ↗ |
| 2023-06-07 | STOLPER MARK | Director | A-Award | A | Stock Option (Right to Buy) | 38,250 | 5.38 | 205.8K | 38,250 | — | ↗ |
| 2023-06-07 | O'Donnell-Tormey Jill | Director | A-Award | A | Stock Option (Right to Buy) | 38,250 | 5.38 | 205.8K | 38,250 | — | ↗ |
| 2023-06-07 | Newton Charles W. | Director | A-Award | A | Stock Option (Right to Buy) | 38,250 | 5.38 | 205.8K | 38,250 | — | ↗ |
| 2023-06-07 | Newcomer Lee Nisley | Director | A-Award | A | Stock Option (Right to Buy) | 38,250 | 5.38 | 205.8K | 38,250 | — | ↗ |
| 2023-04-01 | Stilwell McDavid | Officer | F-InKind | D | Common Stock | 3,457 | 6.84 | 23.6K | 102,252 | — | ↗ |
| 2023-04-01 | Reider Paul | Officer | F-InKind | D | Common Stock | 2,451 | 6.84 | 16.8K | 87,053 | — | ↗ |
| 2023-03-31 | Vexler Vladimir | Officer | F-InKind | D | Common Stock | 16,278 | 6.84 | 111.3K | 116,361 | — | ↗ |
| 2023-03-27 | McMichael Bryan J | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 6.00 | 150.0K | 25,000 | — | ↗ |
| 2023-03-20 | Reider Paul | Officer | — | D | Common Stock | 0 | 0.00 | — | 89,504 | — | ↗ |
| 2023-01-20 | Vexler Vladimir | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 131,323 | — | ↗ |
| 2023-01-20 | Stilwell McDavid | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 104,243 | — | ↗ |
| 2023-01-20 | McMichael Bryan J | Officer | A-Award | A | Common Stock | 12,500 | 0.00 | — | 26,386 | — | ↗ |
| 2023-01-20 | Lanfear Dennis M | Officer | A-Award | A | Common Stock | 86,250 | 0.00 | — | 654,853 | — | ↗ |
| 2023-01-11 | Vexler Vladimir | Officer | F-InKind | D | Common Stock | 3,602 | 10.26 | 37.0K | 91,323 | — | ↗ |
| 2023-01-10 | Vexler Vladimir | Officer | F-InKind | D | Common Stock | 3,602 | 9.85 | 35.5K | 94,925 | — | ↗ |
| 2023-01-07 | McMichael Bryan J | Officer | F-InKind | D | Common Stock | 1,699 | 9.58 | 16.3K | 13,886 | — | ↗ |
| 2023-01-05 | Lanfear Dennis M | Officer | A-Award | A | Stock Option (Right to Buy) | 402,500 | 0.00 | — | 402,500 | — | ↗ |
| 2023-01-04 | Vexler Vladimir | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2023-01-04 | Stilwell McDavid | Officer | F-InKind | D | Common Stock | 5,437 | 9.87 | 53.7K | 64,243 | — | ↗ |
| 2023-01-04 | McMichael Bryan J | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2023-01-04 | Lanfear Dennis M | Officer | F-InKind | D | Common Stock | 10,905 | 9.87 | 107.6K | 568,603 | — | ↗ |
| 2022-12-30 | Lanfear Dennis M | Officer | G-Gift | D | Common Stock | 4,000 | 0.00 | — | 432,684 | — | ↗ |
| 2022-09-07 | McMichael Bryan J | Officer | A-Award | A | Stock Option (Right to Buy) | 15,000 | 10.78 | 161.7K | 15,000 | — | ↗ |
| 2022-05-18 | O'Donnell-Tormey Jill | Director | A-Award | A | Stock Option (Right to Buy) | 54,000 | 0.00 | — | 54,000 | — | ↗ |
| 2022-05-04 | Newton Charles W. | Director | A-Award | A | Stock Option (Right to Buy) | 54,000 | 0.00 | — | 54,000 | — | ↗ |
| 2022-04-01 | Vexler Vladimir | Officer | F-InKind | D | Common Stock | 3,458 | 12.85 | 44.4K | 103,963 | — | ↗ |
| 2022-04-01 | Stilwell McDavid | Officer | F-InKind | D | Common Stock | 3,458 | 12.85 | 44.4K | 69,680 | — | ↗ |
| 2022-02-28 | Wahlstrom Mats | Director | A-Award | A | Common Stock | 29,994 | 2.08 | 62.5K | 40,000 | — | ↗ |
| 2022-02-25 | Wahlstrom Mats | Director | A-Award | A | Common Stock | 10,006 | 11.64 | 116.4K | 10,006 | — | ↗ |
| 2022-02-02 | Newcomer Lee Nisley | Director | A-Award | A | Stock Option (Right to Buy) | 54,000 | 12.44 | 671.8K | 54,000 | — | ↗ |
| 2022-01-11 | Vexler Vladimir | Officer | F-InKind | D | Common Stock | 3,583 | 14.36 | 51.5K | 107,421 | — | ↗ |
| 2022-01-10 | Vexler Vladimir | Officer | F-InKind | D | Common Stock | 4,150 | 14.30 | 59.3K | 111,004 | — | ↗ |
| 2022-01-07 | Wahlstrom Mats | Director | A-Award | A | Stock Option (Right to Buy) | 27,000 | 14.67 | 396.1K | 27,000 | — | ↗ |
| 2022-01-07 | TZOUMAKAS KIMBERLY JO | Director | A-Award | A | Stock Option (Right to Buy) | 27,000 | 14.67 | 396.1K | 27,000 | — | ↗ |
| 2022-01-07 | STOLPER MARK | Director | A-Award | A | Stock Option (Right to Buy) | 27,000 | 14.67 | 396.1K | 27,000 | — | ↗ |
| 2022-01-07 | HEALY JAMES | Director | A-Award | A | Stock Option (Right to Buy) | 27,000 | 14.67 | 396.1K | 27,000 | — | ↗ |
| 2022-01-04 | Vexler Vladimir | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 115,154 | — | ↗ |
| 2022-01-04 | Stilwell McDavid | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 15.94 | 1.28M | 80,000 | — | ↗ |
| 2022-01-04 | Lanfear Dennis M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 402,500 | 15.94 | 6.42M | 402,500 | — | ↗ |
| 2021-11-17 | Lanfear Dennis M | Director / Officer | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 436,684 | — | ↗ |
| 2021-10-15 | Stilwell McDavid | Officer | S-Sale | D | Common Stock | 3,507 | 16.80 | 58.9K | 31,611 | — | ↗ |
| 2021-09-29 | HEALY JAMES | Director | S-Sale | D | Common Stock, $0.0001 par value | 286,076 | 16.12 | 4.61M | 0 | — | ↗ |
| 2021-09-28 | HEALY JAMES | Director | S-Sale | D | Common Stock, $0.0001 par value | 48,329 | 17.17 | 829.8K | 286,076 | — | ↗ |
| 2021-09-27 | HEALY JAMES | Director | S-Sale | D | Common Stock, $0.0001 par value | 100,150 | 18.06 | 1.81M | 334,405 | — | ↗ |
| 2021-07-06 | Anicetti Vincent R | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 13.63 | 2.04M | 150,000 | — | ↗ |
| 2021-06-09 | Stilwell McDavid | Officer | P-Purchase | A | Common Stock | 3,700 | 13.42 | 49.7K | 35,118 | — | ↗ |
| 2021-06-08 | Lanfear Dennis M | Director / Officer | M-Exempt | A | Common Stock | 31,054 | 0.42 | 12.9K | 524,312 | — | ↗ |
| 2021-06-06 | Lanfear Dennis M | Director / Officer | M-Exempt | A | Common Stock | 300,000 | 0.42 | 125.0K | 493,258 | — | ↗ |
| 2021-05-21 | STOLPER MARK | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 13.48 | 269.6K | 20,000 | — | ↗ |
| 2021-05-21 | MENDELSON ALAN C | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 13.48 | 269.6K | 20,000 | — | ↗ |
| 2021-04-28 | Vexler Vladimir | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 73,386 | — | ↗ |
| 2021-04-28 | Stilwell McDavid | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 14.76 | 738.0K | 50,000 | — | ↗ |
| 2021-04-28 | Anicetti Vincent R | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 73,402 | — | ↗ |
| 2021-03-09 | Vexler Vladimir | Officer | M-Exempt | A | Common Stock | 57,812 | 10.05 | 581.0K | 167,626 | — | ↗ |
| 2021-03-08 | Stilwell McDavid | Officer | — | D | Common Stock | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2021-03-05 | Anicetti Vincent R | Officer | S-Sale | D | Common Stock | 6,337 | 15.46 | 98.0K | 53,402 | — | ↗ |
| 2021-02-17 | Anicetti Vincent R | Officer | M-Exempt | A | Common Stock | 2,488 | 2.50 | 6.2K | 62,227 | — | ↗ |
| 2021-02-01 | Viret Jean-Frederic | Officer | M-Exempt | A | Common Stock | 7,402 | 10.05 | 74.4K | 68,697 | — | ↗ |
| 2021-02-01 | Vexler Vladimir | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 17.60 | 880.0K | 50,000 | — | ↗ |
| 2021-02-01 | Lanfear Dennis M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 17.60 | 2.20M | 125,000 | — | ↗ |
| 2021-01-25 | Viret Jean-Frederic | Officer | M-Exempt | A | Common Stock | 40,000 | 10.05 | 402.0K | 107,439 | — | ↗ |
| 2021-01-23 | Lanfear Dennis M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 18.33 | 9.17M | 500,000 | — | ↗ |
| 2021-01-19 | Anicetti Vincent R | Officer | S-Sale | D | Common Stock | 2,500 | 17.94 | 44.9K | 59,739 | — | ↗ |
| 2021-01-11 | Wahlstrom Mats | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 17.58 | 351.6K | 20,000 | — | ↗ |
| 2021-01-11 | Viret Jean-Frederic | Officer | A-Award | A | Common Stock | 31,250 | 0.00 | — | 67,439 | — | ↗ |
| 2021-01-11 | Vexler Vladimir | Officer | A-Award | A | Common Stock | 31,250 | 0.00 | — | 65,146 | — | ↗ |
| 2021-01-11 | TZOUMAKAS KIMBERLY JO | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 17.58 | 351.6K | 20,000 | — | ↗ |
| 2021-01-11 | Szela Mary T | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 17.58 | 351.6K | 20,000 | — | ↗ |
| 2021-01-11 | NUSSBAUM SAMUEL R MD | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 17.58 | 351.6K | 20,000 | — | ↗ |
| 2021-01-11 | LAWLIS V BRYAN | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 17.58 | 351.6K | 20,000 | — | ↗ |
| 2021-01-11 | HEALY JAMES | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 17.58 | 351.6K | 20,000 | — | ↗ |
| 2021-01-11 | Anicetti Vincent R | Officer | A-Award | A | Stock Option (Right to Buy) | 62,500 | 17.58 | 1.10M | 62,500 | — | ↗ |
| 2021-01-10 | Viret Jean-Frederic | Officer | F-InKind | D | Common Stock | 4,080 | 18.18 | 74.2K | 36,189 | — | ↗ |
| 2021-01-10 | Vexler Vladimir | Officer | F-InKind | D | Common Stock | 4,080 | 18.18 | 74.2K | 33,896 | — | ↗ |
| 2021-01-10 | Anicetti Vincent R | Officer | F-InKind | D | Common Stock | 4,080 | 18.18 | 74.2K | 28,489 | — | ↗ |
| 2021-01-05 | STOLPER MARK | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 16.85 | 674.0K | 40,000 | — | ↗ |
| 2021-01-05 | MENDELSON ALAN C | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 16.85 | 674.0K | 40,000 | — | ↗ |
| 2020-12-17 | Anicetti Vincent R | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 2.50 | 6.3K | 4,988 | — | ↗ |
| 2020-12-10 | Vexler Vladimir | Officer | M-Exempt | A | Common Stock | 17,626 | 2.08 | 36.7K | 54,299 | — | ↗ |
| 2020-12-09 | Vexler Vladimir | Officer | M-Exempt | A | Common Stock | 30,000 | 2.08 | 62.5K | 86,185 | — | ↗ |
| 2020-12-07 | Anicetti Vincent R | Officer | S-Sale | D | Common Stock | 8,791 | 18.42 | 161.9K | 32,569 | — | ↗ |
| 2020-12-04 | Anicetti Vincent R | Officer | M-Exempt | A | Common Stock | 16,709 | 12.70 | 212.2K | 81,569 | — | ↗ |
| 2020-12-03 | Anicetti Vincent R | Officer | S-Sale | D | Common Stock | 49,756 | 18.67 | 929.1K | 32,569 | — | ↗ |
| 2020-11-18 | Anicetti Vincent R | Officer | M-Exempt | A | Common Stock | 4,283 | 12.70 | 54.4K | 36,852 | — | ↗ |
| 2020-11-17 | Viret Jean-Frederic | Officer | M-Exempt | A | Common Stock, $0.0001 par value | 1,500 | 13.50 | 20.3K | 40,269 | — | ↗ |
| 2020-11-17 | Anicetti Vincent R | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 2.50 | 6.3K | 7,488 | — | ↗ |
| 2020-10-19 | Anicetti Vincent R | Officer | M-Exempt | A | Common Stock | 717 | 12.70 | 9.1K | 51,773 | — | ↗ |
| 2020-10-14 | Viret Jean-Frederic | Officer | S-Sale | D | Common Stock, $0.0001 par value | 6,144 | 19.00 | 116.7K | 40,423 | — | ↗ |
| 2020-09-29 | HEALY JAMES | Director | J-Other | A | Common Stock, $0.0001 par value | 213,546 | 0.00 | — | 434,555 | — | ↗ |
| 2020-09-17 | Anicetti Vincent R | Officer | S-Sale | D | Common Stock | 5,000 | 18.84 | 94.2K | 48,556 | — | ↗ |
| 2020-08-28 | HEALY JAMES | Director | J-Other | D | Common Stock, $0.0001 par value | 983,221 | 0.00 | — | 950,000 | — | ↗ |
| 2020-08-17 | Anicetti Vincent R | Officer | M-Exempt | A | Common Stock | 2,500 | 12.70 | 31.8K | 53,556 | — | ↗ |
| 2020-07-30 | TZOUMAKAS KIMBERLY JO | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 18.15 | 726.0K | 40,000 | — | ↗ |
| 2020-07-17 | Anicetti Vincent R | Officer | M-Exempt | D | Stock Option (Right to Buy) | 12,500 | 12.70 | 158.8K | 32,500 | — | ↗ |
| 2020-07-01 | Lanfear Dennis M | Director / Officer | M-Exempt | A | Common Stock, $0.0001 par value | 29,994 | 0.01 | 248.95 | 193,258 | — | ↗ |
| 2020-06-22 | Szela Mary T | Director | S-Sale | D | Common Stock, $0.0001 par value | 54,997 | 17.58 | 966.8K | 0 | — | ↗ |
| 2020-06-17 | Wahlstrom Mats | Director | S-Sale | D | Common Stock, $0.0001 par value | 200,000 | 17.15 | 3.43M | 0 | — | ↗ |
| 2020-06-17 | Anicetti Vincent R | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 2.50 | 6.3K | 19,988 | — | ↗ |
| 2020-05-20 | Viret Jean-Frederic | Officer | S-Sale | D | Common Stock, $0.0001 par value | 1,278 | 17.66 | 22.6K | 46,567 | — | ↗ |
| 2020-05-18 | Anicetti Vincent R | Officer | M-Exempt | A | Common Stock | 2,500 | 2.50 | 6.3K | 51,056 | — | ↗ |
| 2020-04-20 | Anicetti Vincent R | Officer | S-Sale | D | Common Stock | 5,150 | 17.00 | 87.6K | 47,846 | — | ↗ |
| 2020-04-17 | Anicetti Vincent R | Officer | S-Sale | D | Common Stock | 5,000 | 15.57 | 77.9K | 52,996 | — | ↗ |
| 2020-03-03 | Wahlstrom Mats | Director | S-Sale | D | Common Stock, $0.0001 par value | 113,844 | 20.09 | 2.29M | 204,222 | — | ↗ |
| 2020-02-19 | Viret Jean-Frederic | Officer | M-Exempt | A | Common Stock, $0.0001 par value | 3,159 | 10.05 | 31.7K | 50,000 | — | ↗ |
| 2020-02-18 | Anicetti Vincent R | Officer | M-Exempt | A | Common Stock, $0.0001 par value | 2,500 | 12.70 | 31.8K | 60,496 | — | ↗ |
| 2020-01-17 | Anicetti Vincent R | Officer | S-Sale | D | Common Stock, $0.0001 par value | 5,000 | 19.56 | 97.8K | 57,996 | — | ↗ |
| 2020-01-15 | Viret Jean-Frederic | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,318 | 10.05 | 63.5K | 104,728 | — | ↗ |
| 2020-01-12 | HEALY JAMES | Director | M-Exempt | D | Stock Option (Right to Buy) | 20,000 | 12.37 | 247.4K | 0 | — | ↗ |
| 2020-01-10 | Wahlstrom Mats | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 17.73 | 354.6K | 20,000 | — | ↗ |
| 2020-01-10 | Viret Jean-Frederic | Officer | F-InKind | D | Common Stock, $0.0001 par value | 7,077 | 17.73 | 125.5K | 15,591 | — | ↗ |
| 2020-01-10 | Vexler Vladimir | Officer | A-Award | A | Common Stock, $0.0001 par value | 31,250 | 0.00 | — | 56,185 | — | ↗ |
| 2020-01-10 | Szela Mary T | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 17.73 | 354.6K | 20,000 | — | ↗ |
| 2020-01-10 | Satvat Ali J. | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 17.73 | 354.6K | 20,000 | — | ↗ |
| 2020-01-10 | Richards Christos | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 17.73 | 354.6K | 20,000 | — | ↗ |
| 2020-01-10 | NUSSBAUM SAMUEL R MD | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 17.73 | 354.6K | 20,000 | — | ↗ |
| 2020-01-10 | Lanfear Dennis M | Director / Officer | F-InKind | D | Common Stock, $0.0001 par value | 21,516 | 17.73 | 381.5K | 163,264 | — | ↗ |
| 2020-01-10 | LAWLIS V BRYAN | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 17.73 | 354.6K | 20,000 | — | ↗ |
| 2020-01-10 | HEALY JAMES | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 17.73 | 354.6K | 20,000 | — | ↗ |
| 2020-01-10 | Anicetti Vincent R | Officer | F-InKind | D | Common Stock, $0.0001 par value | 7,146 | 17.73 | 126.7K | 31,746 | — | ↗ |
| 2020-01-09 | HEALY JAMES | Director | M-Exempt | A | Common Stock, $0.0001 par value | 20,000 | 10.05 | 201.0K | 50,086 | — | ↗ |
| 2019-12-30 | V-Sciences Investments Pte Ltd | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 7,381,116 | — | ↗ |
| 2019-12-16 | Anicetti Vincent R | Officer | M-Exempt | A | Common Stock, $0.0001 par value | 2,500 | 2.50 | 6.3K | 21,826 | — | ↗ |
| 2019-11-21 | Lanfear Dennis M | Director / Officer | S-Sale | D | Common Stock, $0.0001 par value | 12,500 | 18.56 | 232.0K | 446,684 | — | ↗ |
| 2019-11-20 | Viret Jean-Frederic | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,159 | 10.05 | 31.7K | 111,046 | — | ↗ |
| 2019-11-20 | Lanfear Dennis M | Director / Officer | S-Sale | D | Common Stock, $0.0001 par value | 825,000 | 18.00 | 14.85M | 459,184 | — | ↗ |
| 2019-11-18 | Viret Jean-Frederic | Officer | S-Sale | D | Common Stock, $0.0001 par value | 3,112 | 18.88 | 58.8K | 3,303 | — | ↗ |
| 2019-11-14 | Anicetti Vincent R | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 2.50 | 6.3K | 37,488 | — | ↗ |
| 2019-10-18 | Viret Jean-Frederic | Officer | S-Sale | D | Common Stock, $0.0001 par value | 1,388 | 19.02 | 26.4K | 6,385 | — | ↗ |
| 2019-10-16 | Viret Jean-Frederic | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,159 | 10.05 | 31.7K | 114,205 | — | ↗ |
| 2019-10-14 | Anicetti Vincent R | Officer | M-Exempt | A | Common Stock, $0.0001 par value | 2,500 | 2.50 | 6.3K | 21,810 | — | ↗ |
| 2019-09-23 | Viret Jean-Frederic | Officer | S-Sale | D | Common Stock, $0.0001 par value | 740 | 21.78 | 16.1K | 7,773 | — | ↗ |
| 2019-09-18 | Viret Jean-Frederic | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,159 | 10.05 | 31.7K | 117,364 | — | ↗ |
| 2019-09-16 | Anicetti Vincent R | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 2.50 | 6.3K | 42,488 | — | ↗ |
| 2019-08-21 | Viret Jean-Frederic | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,318 | 10.05 | 63.5K | 120,523 | — | ↗ |
| 2019-08-19 | Viret Jean-Frederic | Officer | S-Sale | D | Common Stock, $0.0001 par value | 3,000 | 19.04 | 57.1K | 8,513 | — | ↗ |
| 2019-08-14 | Anicetti Vincent R | Officer | S-Sale | D | Common Stock, $0.0001 par value | 2,500 | 19.00 | 47.5K | 19,310 | — | ↗ |
| 2019-07-15 | Anicetti Vincent R | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 2.50 | 6.3K | 47,488 | — | ↗ |
| 2019-07-02 | HEALY JAMES | Director | S-Sale | D | Common Stock, $0.0001 par value | 160,000 | 22.61 | 3.62M | 1,933,221 | — | ↗ |
| 2019-06-28 | HEALY JAMES | Director | S-Sale | D | Common Stock, $0.0001 par value | 200,000 | 22.05 | 4.41M | 2,093,221 | — | ↗ |
| 2019-06-20 | HEALY JAMES | Director | S-Sale | D | Common Stock, $0.0001 par value | 317,130 | 21.37 | 6.78M | 2,293,221 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-12.0K
Shares Outstanding
117.14M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Dennis M. Lanfear President, Chief Executive Officer and Chairman of the Board of Directors | 1.03M | — | — | 828.1K | 869.3K | 12.9K | 2.74M | 30.26% | ↗ |
| 2 | 2025 | Paul Reider Former Chief Commercial Officer | 217.7K | — | — | 347.8K | — | 662.0K | 1.23M | 28.33% | ↗ |
| 3 | 2025 | Bryan McMichael Chief Financial Officer | 543.7K | — | — | 314.2K | 237.7K | 7.5K | 1.10M | 28.48% | ↗ |
| 4 | 2024 | Dennis M. Lanfear President, Chief Executive Officer and Chairman of the Board of Directors | 1.01M | — | — | 2.87M | 902.2K | 13.6K | 4.80M | 59.83% | ↗ |
| 5 | 2024 | Paul Reider Former Chief Commercial Officer | 559.2K | — | — | 732.0K | 263.0K | 103.2K | 1.66M | 44.17% | ↗ |
| 6 | 2024 | Paul Reider Chief Commercial Officer | 559.2K | — | — | 732.0K | 263.0K | 103.2K | 1.66M | 44.17% | ↗ |
| 7 | 2024 | Bryan McMichael Chief Financial Officer | 467.8K | — | — | 320.8K | 236.8K | 7.5K | 1.03M | 31.06% | ↗ |
| 8 | 2023 | Dennis M. Lanfear President, Chief Executive Officer and Chairman of the Board of Directors | 982.9K | — | 778.0K | 3.30M | 829.9K | 9.5K | 5.90M | 69.10% | ↗ |
| 9 | 2023 | McDavid Stilwell former Chief Financial Officer | 522.9K | — | 449.6K | 744.2K | — | 588.0K | 2.30M | 51.80% | ↗ |
| 10 | 2023 | Vladimir Vexler, Ph.D. former Chief Scientific Officer | 182.8K | — | 360.8K | 767.3K | — | 837.8K | 2.15M | 52.50% | ↗ |
| 11 | 2023 | Paul Reider Chief Commercial Officer | 537.7K | — | 360.8K | 715.7K | 241.5K | 74.9K | 1.93M | 55.76% | ↗ |
| 12 | 2023 | Paul Reider Chief Commercial Officer | 537.7K | — | 360.8K | 715.7K | 241.5K | 74.9K | 1.93M | 55.76% | ↗ |
| 13 | 2023 | Bryan McMichael Chief Financial Officer | 445.7K | — | 112.8K | 342.4K | 161.8K | 7.5K | 1.07M | 42.53% | ↗ |
| 14 | 2023 | Bryan McMichael Chief Financial Officer | 445.7K | — | 112.8K | 342.4K | 161.8K | 7.5K | 1.07M | 42.53% | ↗ |
| 15 | 2022 | Dennis M. Lanfear President, Chief Executive Officer and Chairman of the Board of Directors | 945.0K | — | 1.37M | 3.70M | 840.0K | 9.5K | 6.87M | 73.87% | ↗ |
| 16 | 2022 | Vladimir Vexler, Ph.D. Chief Scientific Officer | 537.6K | — | 637.6K | 734.8K | 234.7K | 7.5K | 2.15M | 63.77% | ↗ |
| 17 | 2022 | Vladimir Vexler, Ph.D. former Chief Scientific Officer | 537.6K | — | 637.6K | 734.8K | 234.7K | 7.5K | 2.15M | 63.77% | ↗ |
| 18 | 2022 | McDavid Stilwell Chief Financial Officer | 503.3K | — | 637.6K | 734.8K | 208.8K | 7.5K | 2.09M | 65.60% | ↗ |
| 19 | 2022 | McDavid Stilwell former Chief Financial Officer | 503.3K | — | 637.6K | 734.8K | 208.8K | 7.5K | 2.09M | 65.60% | ↗ |
| 20 | 2021 | Dennis M. Lanfear President, Chief Executive Officer and Chairman of the Board of Directors | 885.3K | — | — | 6.73M | 977.0K | 2.0K | 8.59M | 78.31% | ↗ |
| 21 | 2021 | Vincent Anicetti Chief Operating Officer | 505.1K | — | 1.53M | 1.84M | 292.1K | — | 4.17M | 80.87% | ↗ |
| 22 | 2021 | Vladimir Vexler, Ph.D. former Chief Scientific Officer | 508.9K | — | 844.6K | 1.17M | 269.4K | — | 2.80M | 72.17% | ↗ |
| 23 | 2021 | Vladimir Vexler, Ph.D. Chief Scientific Officer | 508.9K | — | 844.6K | 1.17M | 269.4K | — | 2.80M | 72.17% | ↗ |
| 24 | 2021 | McDavid Stilwell Chief Financial Officer | 485.5K | — | 295.2K | 431.6K | 256.9K | 13.6K | 1.48M | 49.01% | ↗ |
| 25 | 2021 | McDavid Stilwell former Chief Financial Officer | 485.5K | — | 295.2K | 431.6K | 256.9K | 13.6K | 1.48M | 49.01% | ↗ |
| 26 | 2021 | McDavid Stilwell Chief Financial Officer | 485.5K | — | 295.2K | 431.6K | 256.9K | 13.6K | 1.48M | 49.01% | ↗ |
| 27 | 2021 | Jean-Frédéric Viret, Ph.D. Former Chief Financial Officer | 150.5K | — | 549.4K | 652.1K | — | — | 1.35M | 88.87% | ↗ |
| 28 | 2020 | Dennis M. Lanfear President, Chief Executive Officer and Chairman of the Board of Directors | 856.8K | — | — | 5.45M | 965.1K | 2.8K | 7.28M | 74.93% | ↗ |
| 29 | 2020 | Jean-Frédéric Viret, Ph.D. Former Chief Financial Officer | 536.2K | — | 554.1K | 681.8K | 298.5K | — | 2.07M | 59.69% | ↗ |
| 30 | 2020 | Vincent Anicetti Chief Operating Officer | 491.9K | — | 554.1K | 681.8K | 301.6K | 1.9K | 2.03M | 60.84% | ↗ |
| 31 | 2020 | Vladimir Vexler, Ph.D. Chief Scientific Officer | 480.7K | — | 554.1K | 681.8K | 287.5K | 308.00 | 2.00M | 61.66% | ↗ |
| 32 | 2019 | Dennis M. Lanfear President, Chief Executive Officer and Chairman of the Board of Directors | 750.7K | 195.7K | — | 3.55M | 863.9K | 4.2K | 5.36M | 66.16% | ↗ |
| 33 | 2019 | Dennis M. Lanfear President, Chief Executive Officer and Chairman of the Board of Directors | 750.7K | 195.7K | — | 3.55M | 863.9K | 4.2K | 5.36M | 66.16% | ↗ |
| 34 | 2019 | Darlene P. Horton, M.D. | 304.1K | 75.0K | — | 2.77M | — | 484.7K | 3.63M | 76.20% | ↗ |
| 35 | 2019 | Jean-Fr é d é ric Viret, Ph.D. | 493.0K | 63.4K | — | 993.2K | 279.9K | — | 1.83M | 54.29% | ↗ |
| 36 | 2019 | Jean-Frédéric Viret, Ph.D. Former Chief Financial Officer | 493.0K | 63.4K | — | 993.2K | 279.9K | — | 1.83M | 54.29% | ↗ |
| 37 | 2019 | Vincent Anicetti Chief Operating Officer | 469.4K | 64.1K | — | 993.2K | 282.9K | 1.4K | 1.81M | 54.85% | ↗ |
| 38 | 2019 | Vincent Anicetti Chief Operating Officer | 469.4K | 64.1K | — | 993.2K | 282.9K | 1.4K | 1.81M | 54.85% | ↗ |
| 39 | 2019 | Vladimir Vexler, Ph.D. Chief Scientific Officer | 447.5K | 58.3K | — | 993.2K | 257.3K | 888.00 | 1.76M | 56.52% | ↗ |
| 40 | 2019 | Vladimir Vexler, Ph.D. Chief Scientific Officer | 447.5K | 58.3K | — | 993.2K | 257.3K | 888.00 | 1.76M | 56.52% | ↗ |
| 41 | 2018 | Dennis M. Lanfear President, Chief Executive Officer and Chairman of the Board of Directors | 702.3K | 22.2K | — | 2.60M | 599.6K | — | 3.92M | 66.22% | ↗ |
| 42 | 2018 | Dennis M. Lanfear President, Chief Executive Officer and Chairman of the Board of Directors | 702.3K | 22.2K | — | 2.60M | 599.6K | — | 3.92M | 66.22% | ↗ |
| 43 | 2018 | Vincent Anicetti Chief Operating Officer | 418.7K | 7.5K | — | 1.19M | 202.7K | — | 1.82M | 65.41% | ↗ |
| 44 | 2018 | Vincent Anicetti Chief Operating Officer | 418.7K | 7.5K | — | 1.19M | 202.7K | — | 1.82M | 65.41% | ↗ |
| 45 | 2018 | Vincent Anicetti Chief Operating Officer | 418.7K | 7.5K | — | 1.19M | 202.7K | — | 1.82M | 65.41% | ↗ |
| 46 | 2018 | Barbara Finck, M.D. Chief Medical Officer | 482.4K | 8.0K | — | 843.6K | 214.6K | — | 1.55M | 54.48% | ↗ |
| 47 | 2018 | Jean-Frédéric Viret, Ph.D. Chief Financial Officer | 428.2K | 7.4K | — | 843.6K | 199.0K | — | 1.48M | 57.07% | ↗ |
| 48 | 2018 | Jean-Frédéric Viret, Ph.D. Former Chief Financial Officer | 428.2K | 7.4K | — | 843.6K | 199.0K | — | 1.48M | 57.07% | ↗ |
| 49 | 2018 | Vladimir Vexler, Ph.D. Chief Scientific Officer | 393.1K | 6.9K | — | 769.6K | 185.6K | — | 1.36M | 56.79% | ↗ |
| 50 | 2018 | Vladimir Vexler, Ph.D. Chief Scientific Officer | 393.1K | 6.9K | — | 769.6K | 185.6K | — | 1.36M | 56.79% | ↗ |
| 51 | 2018 | Vladimir Vexler, Ph.D. Chief Scientific Officer | 393.1K | 6.9K | — | 769.6K | 185.6K | — | 1.36M | 56.79% | ↗ |
| 52 | 2017 | Dennis M. Lanfear President, Chief Executive Officer and Chairman of the Board of Directors | 656.0K | — | — | 1.71M | 297.5K | — | 2.66M | 64.17% | ↗ |
| 53 | 2017 | Barbara Finck, M.D. Chief Medical Officer | 469.8K | — | — | 572.1K | 107.0K | — | 1.15M | 49.79% | ↗ |
| 54 | 2017 | Barbara Finck, M.D. Chief Medical Officer | 469.8K | — | — | 572.1K | 107.0K | — | 1.15M | 49.79% | ↗ |
| 55 | 2017 | Jean-Frédéric Viret, Ph.D. Chief Financial Officer | 410.6K | — | — | 572.1K | 98.8K | — | 1.08M | 52.90% | ↗ |
| 56 | 2017 | Jean-Frédéric Viret, Ph.D. Chief Financial Officer | 410.6K | — | — | 572.1K | 98.8K | — | 1.08M | 52.90% | ↗ |
| 57 | 2017 | Peter Watler Chief Technical Officer | 315.8K | — | — | 572.1K | 83.7K | — | 971.5K | 58.89% | ↗ |
| 58 | 2016 | Dennis M. Lanfear President, Chief Executive Office and Chairman of the Board | 652.6K | — | — | 3.65M | 469.0K | — | 4.77M | 76.47% | ↗ |
| 59 | 2016 | Barbara Finck, M.D. Chief Medical Officer | 429.4K | — | — | 883.1K | 174.7K | — | 1.49M | 59.38% | ↗ |
| 60 | 2016 | Barbara Finck Chief Medical Officer | 429.4K | — | — | 883.1K | 174.7K | — | 1.49M | 59.38% | ↗ |
| 61 | 2016 | Jean-Frédéric Viret, Ph.D. Chief Financial Officer | 389.2K | — | — | 883.1K | 158.8K | — | 1.43M | 61.71% | ↗ |
| 62 | 2016 | Jean-Frédéric Viret, Ph.D. Chief Financial Officer | 389.2K | — | — | 883.1K | 158.8K | — | 1.43M | 61.71% | ↗ |
| 63 | 2016 | Peter Watler Chief Technical Officer | 365.4K | — | — | 883.1K | 147.0K | — | 1.40M | 63.28% | ↗ |
| 64 | 2016 | Alan C. Herman, Ph.D. Chief Scientific Officer | 311.8K | — | — | 779.2K | 40.7K | 56.4K | 1.19M | 65.58% | ↗ |
| 65 | 2015 | Dennis M. Lanfear President, Chief Executive Office and Chairman of the Board | 546.2K | — | — | 8.16M | 449.4K | 3.8K | 9.16M | 89.09% | ↗ |
| 66 | 2015 | Barbara Finck Chief Medical Officer | 410.4K | — | — | 1.83M | 128.4K | 182.00 | 2.37M | 77.22% | ↗ |
| 67 | 2015 | Jean-Frédéric Viret, Ph.D. Chief Financial Officer | 363.3K | — | — | 1.83M | 126.8K | 1.9K | 2.32M | 78.78% | ↗ |
| 68 | 2015 | Peter Watler Chief Technical Officer | 356.8K | — | — | 1.83M | 112.8K | 1.9K | 2.30M | 79.48% | ↗ |
| 69 | 2015 | Peter Watler Chief Technical Officer | 356.8K | — | — | 1.83M | 112.8K | 1.9K | 2.30M | 79.48% | ↗ |
| 70 | 2015 | Alan C. Herman, Ph.D. Chief Scientific Officer | 404.7K | — | — | 913.2K | 129.8K | 142.00 | 1.45M | 63.07% | ↗ |
| 71 | 2014 | Dennis M. Lanfear President, Chief Executive Office and Chairman of the Board | 450.2K | — | — | 4.67M | 506.3K | 37.5K | 5.66M | 82.45% | ↗ |
| 72 | 2014 | George Montgomery | 272.7K | — | — | 3.60M | 87.5K | 94.5K | 4.05M | 88.78% | ↗ |
| 73 | 2014 | Alan C. Herman, Ph.D. Chief Scientific Officer | 352.2K | — | — | 1.95M | 105.0K | 51.6K | 2.46M | 79.31% | ↗ |
| 74 | 2014 | Jean-Frédéric Viret, Ph.D. Chief Financial Officer | 102.4K | — | — | 1.47M | 36.0K | 658.00 | 1.61M | 91.36% | ↗ |
| 75 | 2014 | Jean-Frédéric Viret, Ph.D. Chief Financial Officer | 102.4K | — | — | 1.47M | 36.0K | 658.00 | 1.61M | 91.36% | ↗ |
| 76 | 2014 | Barbara Finck Chief Medical Officer | 379.8K | — | — | — | 168.8K | 415.00 | 548.9K | 0.00% | ↗ |
| 77 | 2013 | Dennis M. Lanfear President, Chief Executive Office and Chairman of the Board | 400.0K | 337.6K | — | 638.1K | — | 3.9K | 1.38M | 46.25% | ↗ |
| 78 | 2013 | Barbara Finck Chief Medical Officer | 330.4K | 112.6K | — | — | — | 321.00 | 837.9K | 0.00% | ↗ |
| 79 | 2013 | Alan C. Herman, Ph.D. Chief Scientific Officer | 296.1K | 105.1K | — | 121.2K | — | 321.00 | 522.8K | 23.19% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2026-05-05 | DEFA14A | ↗ |
| 2026-04-20 | DEF 14A | ↗ |
| 2026-04-14 | DEFA14A | ↗ |
| 2026-04-09 | PRE 14A | ↗ |
| 2025-04-29 | DEFA14A | ↗ |
| 2025-04-29 | DEF 14A | ↗ |
| 2025-03-04 | DEFA14A | ↗ |
| 2025-01-30 | DEFA14A | ↗ |
| 2025-01-14 | DEFA14A | ↗ |
| 2024-12-04 | DEFA14A | ↗ |
| 2024-12-04 | DEFA14A | ↗ |
| 2024-12-03 | DEFA14A | ↗ |
| 2024-12-03 | DEFA14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dennis Lanfear | Chairman, President & Chief Executive Officer | 2M | male |
| Sameer Goregaoker | Chief Commercial Officer | 854.1K | male |
| Bryan J. McMichael | Chief Financial Officer | 788.9K | male |
| Michael Chen | Senior Vice President of Commercial Analytics & Trade | — | male |
| Rebecca Sunshine | Chief Human Resources Officer | — | female |
| Rosh Dias MRCP | Chief Medical Officer | — | — |
| Andy Rittenberg | Chief Legal Officer | — | male |
| Theresa Lavallee | Chief Development Officer & Chairman of Scientific Advisory Board | — | — |
| Arvind Sood | Chief Strategy & Corporate Affairs Officer | — | male |
| Carrie Graham | Vice President of Investor Relations & Advocacy | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CHRS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
